[ad_1]
Notice of highest interest about vaccine COVID developed by the AstraZeneca company together with the University of Oxford. The vaccine could be available for use by the end of December, said the chief executive of the pharmaceutical manufacturer. The company is now awaiting approval from the drug market regulatory authorities.
The vaccine developed by this company entered the third phase of clinical trials in September, but was temporarily halted due to concerns about the health of a volunteer in the UK. Subsequently, they resumed. AstraZeneca is considered one of the most promising candidates in the world in terms of finding an effective anti-COVID-19 treatment.
Sandra Alexiu, president of the Bucharest-Ilfov Family Doctors Association and member of the vaccination group of the National Society of Family Doctors, says this vaccine will be easier to administer than others currently in development.
„Several vaccines are in phase 3, in an advanced testing phase. Is being tested for 30,000 subjects and of whom we already know some things. It is part of a series of vaccines that are already reserved and where will be approved“Alexiu said on Digi24.
„They will also arrive in Romania, they notified us in a press release. It is one of the vaccines that will facilitate transportation and administration a little less, because it is a vaccine that behaves in the same way as the ones we use today. For the other vaccines in question, the question of special conditions of transport and administration was raised.She added.
„The Astra Zeneca vaccine, made with specialists at Oxford, is an adenovirus vaccine. This means that it uses an attenuated virus, somehow dormant, to introduce into the body that signal that stimulates the body to produce antibodies and that reacts to the encounter with the coronavirus. We are talking about an administration of two doses, at least as it is currently known, two doses at intervals of one month.
If it is published and this can happen, we and the EU will benefit, but some things need to be done. We need to establish a good collaboration between all the actors involved in this, a very good organization of vaccination, communication to the population and the establishment of risk groups. This is an important desideratum, considering that we are not going to receive doses for the entire population, ”Alexiu also said.
Editing: Monica Bonea
